These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36293222)

  • 21. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
    Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
    Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of early oxidative stress following the use of radiotheranostics agents 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors; radioprotective effect of vitamin C.
    Jafari E; Ahmadzadehfar H; Bagheri D; Amini A; Assadi M
    Nucl Med Commun; 2021 Mar; 42(3):325-331. PubMed ID: 33306634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
    Kulkarni HR; Schuchardt C; Baum RP
    Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In Vivo Instability of
    Lubberink M; Wilking H; Öst A; Ilan E; Sandström M; Andersson C; Fröss-Baron K; Velikyan I; Sundin A
    J Nucl Med; 2020 Sep; 61(9):1337-1340. PubMed ID: 32005767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
    Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H
    Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG Therapies.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2016 Feb; 41(2):137-41. PubMed ID: 26447382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
    Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
    Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The radiosensitizer Onalespib increases complete remission in
    Lundsten S; Spiegelberg D; Raval NR; Nestor M
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):980-990. PubMed ID: 31912256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors.
    Vida Navas EM; Martínez Lorca A; Sancho Gutiérrez A; Sanz Gómez L; Navarro Martínez T; Grande Pulido E; Carrato Mena A; Gajate Borau P
    Front Endocrinol (Lausanne); 2021; 12():676973. PubMed ID: 33935979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
    Kunikowska J; Królicki L; Hubalewska-Dydejczyk A; Mikołajczak R; Sowa-Staszczak A; Pawlak D
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1788-97. PubMed ID: 21553086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.
    Bodei L; Cremonesi M; Grana CM; Fazio N; Iodice S; Baio SM; Bartolomei M; Lombardo D; Ferrari ME; Sansovini M; Chinol M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2125-35. PubMed ID: 21892623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guidance on
    Abbott A; Sakellis CG; Andersen E; Kuzuhara Y; Gilbert L; Boyle K; Kulke MH; Chan JA; Jacene HA; Van den Abbeele AD
    J Nucl Med Technol; 2018 Sep; 46(3):237-244. PubMed ID: 30076245
    [No Abstract]   [Full Text] [Related]  

  • 35. NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors.
    Elf AK; Bernhardt P; Hofving T; Arvidsson Y; Forssell-Aronsson E; Wängberg B; Nilsson O; Johanson V
    J Nucl Med; 2017 Feb; 58(2):288-292. PubMed ID: 27688470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver and bone metastases from small bowel neuroendocrine tumor respond to 177Lu-DOTATATE induction and maintenance therapies.
    Makis W; McCann K; Buteau FA; McEwan AJ
    Clin Nucl Med; 2015 Feb; 40(2):162-5. PubMed ID: 25243941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac metastases of neuroendocrine tumors treated with 177Lu DOTATATE peptide receptor radionuclide therapy or 131I-MIBG therapy.
    Makis W; McCann K; Bryanton M; McEwan AJ
    Clin Nucl Med; 2015 Dec; 40(12):962-4. PubMed ID: 26359563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and outcomes of
    Lin E; Chen T; Little A; Holliday L; Roach P; Butler P; Hosking E; Bailey E; Elison B; Currow D
    Intern Med J; 2019 Oct; 49(10):1268-1277. PubMed ID: 31062490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatopulmonary Shunt Reduction With 177Lu-DOTATATE Therapy.
    Acar E; Çapa Kaya G; Durak H
    Clin Nucl Med; 2016 Nov; 41(11):866-871. PubMed ID: 27607172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.